» Articles » PMID: 33389263

Nosocomial Infections Associated to COVID-19 in the Intensive Care Unit: Clinical Characteristics and Outcome

Overview
Publisher Springer
Date 2021 Jan 3
PMID 33389263
Citations 150
Authors
Affiliations
Soon will be listed here.
Abstract

Bacterial and fungal co-infection has been reported in patients with COVID-19, but there is limited experience on these infections in critically ill patients. The objective of this study was to assess the characteristics and ouctome of ICU-acquired infections in COVID-19 patients. We conducted a retrospective single-centre, case-control study including 140 patients with severe COVID-19 admitted to the ICU between March and May 2020. We evaluated the epidemiological, clinical, and microbiological features, and outcome of ICU-acquired infections. Fifty-seven patients (40.7%) developed a bacterial or fungal nosocomial infection during ICU stay. Infection occurred after a median of 9 days (IQR 5-11) of admission and was significantly associated with the APACHE II score (p = 0.02). There were 91 episodes of infection: primary (31%) and catheter-related (25%) bloodstream infections were the most frequent, followed by pneumonia (23%), tracheobronchitis (10%), and urinary tract infection (8%) that were produced by a wide spectrum of Gram-positive (55%) and Gram-negative bacteria (30%) as well as fungi (15%). In 60% of cases, infection was associated with septic shock and a significant increase in SOFA score. Overall ICU mortality was 36% (51/140). Infection was significantly associated with death (OR 2.7, 95% CI 1.2-5.9, p = 0.015) and a longer ICU stay (p < 0.001). Bacterial and fungal nosocomial infection is a common complication of ICU admission in patients with COVID-19. It usually presents as a severe form of infection, and it is associated with a high mortality and longer course of ICU stay.

Citing Articles

Detection of O25B-ST131 clone and gene in isolated from patients with COVID-19.

Anwar K PeerJ. 2025; 13:e19011.

PMID: 40061238 PMC: 11890292. DOI: 10.7717/peerj.19011.


The association between early corticosteroid use and the risk of secondary infections in hospitalized patients with COVID-19: a double-edged sword. Results from the international SCCM discovery viral infection and respiratory illness universal study....

Bansal V, Jain N, Lal A, Khedr A, Tekin A, Jama A Front Med (Lausanne). 2025; 12:1466346.

PMID: 40027890 PMC: 11868930. DOI: 10.3389/fmed.2025.1466346.


Impact of healthcare-associated infections on in-hospital outcomes during the COVID-19 era: a multicenter comparative study of 20,942 isolated microorganisms from ICU patients.

Khavandegar A, Siami Z, Rasouli A, Nazemi P, Gull A Front Public Health. 2025; 13:1475221.

PMID: 39991697 PMC: 11842308. DOI: 10.3389/fpubh.2025.1475221.


Yeasts Prefer Daycares and Molds Prefer Private Homes.

Kauserud H, Martin-Sanchez P, Estensmo E, Botnen S, Morgado L, Maurice S Microb Ecol. 2025; 88(1):7.

PMID: 39976768 PMC: 11842513. DOI: 10.1007/s00248-025-02505-4.


Effect of total intravenous-based immediate extubation on patient outcomes in adult liver transplantation: A retrospective cohort study.

Chu Y, Zhang H, Jin B, Liu Y, Yao Y Heliyon. 2025; 11(2):e42108.

PMID: 39906806 PMC: 11791107. DOI: 10.1016/j.heliyon.2025.e42108.


References
1.
Bartoletti M, Pascale R, Cricca M, Rinaldi M, Maccaro A, Bussini L . Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study. Clin Infect Dis. 2020; 73(11):e3606-e3614. PMC: 7454393. DOI: 10.1093/cid/ciaa1065. View

2.
Zhou P, Liu Z, Chen Y, Xiao Y, Huang X, Fan X . Bacterial and fungal infections in COVID-19 patients: A matter of concern. Infect Control Hosp Epidemiol. 2020; 41(9):1124-1125. PMC: 7184139. DOI: 10.1017/ice.2020.156. View

3.
Palomar M, Alvarez-Lerma F, Riera A, Diaz M, Torres F, Agra Y . Impact of a national multimodal intervention to prevent catheter-related bloodstream infection in the ICU: the Spanish experience. Crit Care Med. 2013; 41(10):2364-72. DOI: 10.1097/CCM.0b013e3182923622. View

4.
Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M . Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020; 2(8):e474-e484. PMC: 7314456. DOI: 10.1016/S2665-9913(20)30173-9. View

5.
Chakraborty R, Lam V, Kommineni S, Stromich J, Hayward M, Kristich C . Ceftriaxone Administration Disrupts Intestinal Homeostasis, Mediating Noninflammatory Proliferation and Dissemination of Commensal Enterococci. Infect Immun. 2018; 86(12). PMC: 6246901. DOI: 10.1128/IAI.00674-18. View